Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD).
The exact prevalence of secondary hyperparathyroidism in chronic hemodialysis patients in Somalia is unknown. In this study, we aim to determine the prevalence of SHPT in chronic hemodialysis patients in Mogadishu, Somalia.
This retrospective analysis was done at Mogadishu Somali Turkey training and research hospital, Somalia's largest dialysis center. All > 18-year-old hemodialysis patients from the last year were included. The research excluded parathyroidectomy and steroid, phenytoin, and phenobarbitone individuals. This analysis covered 195 patients. Calcium, phosphate, albumin, vitamin D, urea, creatinine, and other electrolytes were also tested.
Our study included 195 patients who met the inclusion criteria. The mean age was 56.0 ± 17.4 with 49.2% men and 50.88% females. End-stage kidney disease (ESKD) was caused by hypertension in 64.1% of patients and diabetes in 30.8%. The mean hemodialysis time was 7.8 ± 1.3 hours per week and for duration 39.6 ± 15 months. The mean iPTH concentration was 458.59 ± 636.96 pg/mL, phosphate was 4.24 ± 2.15 mg/dL, corrected calcium was 8.70 ± 0.97 mg/dL, and calcium phosphate product was 36.60 ± 19.78 mg/dL. The mean vitamin D concentration was 33.53 ± 19.70. we found that the prevalence of secondary hyperparathyroidism is 65.6%.
We conclude that there is high prevalence of secondary hyperparathyroidism in chronic hemodialysis patients in Somalia and that measures that predict vitamin D response, including sestamibi parathyroid scan and gland volume, should be studied further to prevent this high prevalence.